Clinical Trial Update: Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours [Phase 1]

View source ↗

Summary

This update outlines a Phase 1 study to assess how Rifampicin affects the pharmacokinetics of multiple doses of Cediranib in patients with solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Cediranib (Cediranib)
• Rifampicin

Snippet

Sponsor: AstraZeneca | Conditions: Solid Tumors | Phase 1 | Status: ACTIVE_NOT_RECRUITING